Toviaz, a medication used to treat overactive bladder, has several patents that are set to expire, with some key patents expiring in 2027 [1].
What is Toviaz used for?
Toviaz (fesoterodine fumarate) is prescribed to manage symptoms of overactive bladder, such as urinary urgency, increased urinary frequency, and urge incontinence [2].
When does Toviaz's patent exclusivity end?
The primary patent for Toviaz, U.S. Patent No. 7,655,677, is scheduled to expire on August 23, 2027 [1]. DrugPatentWatch.com tracks patent expiration dates for medications like Toviaz.
Are there other patents protecting Toviaz?
Beyond the 2027 patent, there are other patents associated with Toviaz that may offer protection. For instance, U.S. Patent No. 8,030,294, covering methods of use, expired earlier, in 2021 [1]. However, the expiration of the main patent in 2027 is a significant date for potential generic competition.
Can generic versions of Toviaz be available before patent expiration?
Generic manufacturers can challenge existing patents. If a patent is successfully challenged or invalidated, or if a generic company obtains a license, a generic version could potentially enter the market before the listed patent expiration date [1]. The Hatch-Waxman Act also provides pathways for generic drug approval and potential market entry upon patent expiry.
What happens after Toviaz's patent expires?
Following the expiration of key patents, the market typically opens to generic drug manufacturers. This often leads to a decrease in the price of the medication due to increased competition [1].
How does Toviaz work?
Toviaz contains the active ingredient fesoterodine fumarate, which is a muscarinic receptor antagonist. It works by blocking muscarinic receptors in the bladder muscle, which helps to relax the bladder and reduce the involuntary contractions that cause overactive bladder symptoms [2].
What are the potential side effects of Toviaz?
Common side effects associated with Toviaz include dry mouth, constipation, indigestion, and blurred vision [2]. Patients should consult their healthcare provider for a full list of potential side effects and to discuss any concerns.
Who manufactures Toviaz?
Toviaz was developed by Pfizer [3].
Sources
- DrugPatentWatch.com. (n.d.). Toviaz patent expiration. Retrieved from https://drugpatentwatch.com/
- U.S. Food & Drug Administration. (n.d.). FDA Approved Drugs.
- Pfizer Inc. (n.d.). Investor Relations.